SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Seattle Genetics (SGEN)
An SI Board Since November 2000
Posts SubjectMarks Bans
161 32 0
Emcee:  keokalani'nui Type:  Unmoderated
Introduction Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
36$2m upfront from CRGN for a single antibody deal - Message 20241997 Up to $28m nigel bates-6/22/2004
35I now see a GCOR focus here. Message 19965683richardred-3/30/2004
34I've watch this company for awhile since it's relationship with GCOR in richardred-3/11/2004
33Been thinking the same, and it may be the conjugation tech that is the surprise.keokalani'nui-3/10/2004
32>>Why is this published under the auspices of Fred Hutchinson? Does SGEN hIcebrg-3/10/2004
31I remember the day, many moons ago, when SGEN IPO'd, that you said to treat tuck-3/10/2004
30>>Nat Biotechnol. 2003 Jul;21(7):778-84. Epub 2003 Jun 01. Development otuck-3/10/2004
29This Signals article on armed antibodies features prominent mention of SGEN and tuck-3/10/2004
28EphB2 as a Therapeutic Antibody Drug Target for the Treatment of Colorectal Canckeokalani'nui-2/11/2004
27Just watched the SGEN presentation at JPM. Both Audio and slides available in tIan@SI-1/15/2004
26Seattle Genetics Receives Additional $10 Million From Genentech Under Antibody-Dnigel bates-12/19/2003
25Seattle Genetics Publishes Preclinical Antibody-Drug Conjugate Technology Researtnsaf-6/15/2003
24SGEN is up about 50% over the past five sessions. May 13, 2003-- Seattle GenetiMike McFarland-5/16/2003
23BOTHELL, Wash.--(BUSINESS WIRE)--April 8, 2003--Seattle Genetics, Inc. (Nasdaq:Snigel bates-4/8/2003
22BOTHELL, Wash.--(BUSINESS WIRE)--Oct. 8, 2002--Seattle Genetics, Inc. (Nasdaq:SGnigel bates-10/8/2002
21Seattle Genetics Has Successfully Finished SGN-30 Study DOW JONES NEWSWIRES BOmopgcw-9/5/2002
20Seattle Genetics Announces Antibody-Drug Conjugate Agreement With Genentech BOTnigel bates-4/22/2002
19Seattle Genetics Names H. Perry Fell Chairman DOW JONES NEWSWIRES BOTHELL, Wasmopgcw-4/1/2002
18Celltech and Seattle Genetics Announce Antibody-Drug Conjugate Collaboration SLnigel bates-3/29/2002
17Seattle Genetics Licenses Monoclonal Antibodies DOW JONES NEWSWIRES BOTHELL, Wmopgcw-3/14/2002
16Seattle Genetics Initiates Phase II Clinical Trial with SGN-15 in Lung Cancer Bnigel bates-8/21/2001
15Seattle Genetics Added to Russell 2000 and Russell 3000 Stock Indexes BOTHELL, $Mogul-7/10/2001
14Seattle Genetics Names Morris Rosenberg Vice President, DevelopmentCompany Expa$Mogul-7/10/2001
13I don't see any weakness here..rather a very savy and potentially very profi$Mogul-7/10/2001
12That is interesting. Why? Their deal with Eos last week seems to have been made Icebrg-7/9/2001
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News